News Website

The effect of para-aortic lymphadenectomy on survival in early stage endometrioid grade 3 and non-endometrioid endometrial cancers - BMC Women's Health

The effect of para-aortic lymphadenectomy on survival in early stage endometrioid grade 3 and non-endometrioid endometrial cancers BMC Women's Health

Published: Nov. 19, 2025, 11:24 a.m.

Read Full Article

KEYTRUDA + LENVIMA shows durable 5-year survival benefit in advanced endometrial cancer - Indian Pharma Post

KEYTRUDA + LENVIMA shows durable 5-year survival benefit in advanced endometrial cancer Indian Pharma Post

Published: Oct. 22, 2025, 5:03 p.m.

Read Full Article

Tecentriq Plus Chemo Shows Comparable Survival in Endometrial Cancer - CUREtoday.com

Tecentriq Plus Chemo Shows Comparable Survival in Endometrial Cancer CUREtoday.com

Published: Oct. 19, 2025, 6:39 p.m.

Read Full Article

Atezolizumab Combo Displays Noninferior Survival in Endometrial Cancer - CancerNetwork

Atezolizumab Combo Displays Noninferior Survival in Endometrial Cancer CancerNetwork

Published: Oct. 19, 2025, 4:40 p.m.

Read Full Article

Atezolizumab Combo Displays Noninferior Survival in Endometrial Cancer - cancernetwork.com

Atezolizumab Combo Displays Noninferior Survival in Endometrial Cancer cancernetwork.com

Published: Oct. 19, 2025, 4:40 p.m.

Read Full Article

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - The AI Journal

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen The AI Journal

Published: Oct. 18, 2025, 10:28 a.m.

Read Full Article

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - Business Wire

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen Business Wire

Published: Oct. 18, 2025, 10 a.m.

Read Full Article

Study Explores Impact of Uterine Adenomyosis on Survival Outcomes in Non-Endometrioid Endometrial Cancer - geneonline.com

Study Explores Impact of Uterine Adenomyosis on Survival Outcomes in Non-Endometrioid Endometrial Cancer geneonline.com

Published: Oct. 14, 2025, 6:39 p.m.

Read Full Article

Uterine Adenomyosis Influences Non-Endometrioid Cancer Survival - Bioengineer.org

Uterine Adenomyosis Influences Non-Endometrioid Cancer Survival Bioengineer.org

Published: Oct. 14, 2025, 5:14 p.m.

Read Full Article

Uterine Adenomyosis Influences Non-Endometrioid Cancer Survival - BIOENGINEER.ORG

Uterine Adenomyosis Influences Non-Endometrioid Cancer Survival BIOENGINEER.ORG

Published: Oct. 14, 2025, 5:14 p.m.

Read Full Article

Latest Articles

The effect of para-aortic lymphadenectomy on survival in early stage endometrioid grade 3 and non-endometrioid endometrial cancers - BMC Women's Health

KEYTRUDA + LENVIMA shows durable 5-year survival benefit in advanced endometrial cancer - Indian Pharma Post

Tecentriq Plus Chemo Shows Comparable Survival in Endometrial Cancer - CUREtoday.com

Atezolizumab Combo Displays Noninferior Survival in Endometrial Cancer - CancerNetwork

Atezolizumab Combo Displays Noninferior Survival in Endometrial Cancer - cancernetwork.com

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - The AI Journal

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - Business Wire

Study Explores Impact of Uterine Adenomyosis on Survival Outcomes in Non-Endometrioid Endometrial Cancer - geneonline.com

Uterine Adenomyosis Influences Non-Endometrioid Cancer Survival - Bioengineer.org

Uterine Adenomyosis Influences Non-Endometrioid Cancer Survival - BIOENGINEER.ORG

Subscribe to Our Newsletter